Irritable Bowel Syndrome (IBS) Therapeutics Market Report

Global Irritable Bowel Syndrome (IBS) Therapeutics Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 10, 2022
  • PAGES：212
  • REPORT CODE：GMM807574
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Irritable Bowel Syndrome (IBS) Therapeutics market report explains the definition, types, applications, major countries, and major players of the Irritable Bowel Syndrome (IBS) Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Novartis

    • GlaxoSmithKline

    • Astellas Pharma

    • Ardelyx

    • Ironwood Pharmaceuticals

    • Valeant Pharmaceuticals International

    • Abbott Laboratories

    • Synergy Pharmaceuticals

    • Sucampo Pharmaceuticals

    By Type:

    • Blautix (Strain)

    • Bekinda (IBS-D)

    • SYN-010

    • Tenapanor

    By End-User:

    • Hospital

    • Research

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Irritable Bowel Syndrome (IBS) Therapeutics Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Irritable Bowel Syndrome (IBS) Therapeutics Outlook to 2028- Original Forecasts

    • 2.2 Irritable Bowel Syndrome (IBS) Therapeutics Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Irritable Bowel Syndrome (IBS) Therapeutics Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Irritable Bowel Syndrome (IBS) Therapeutics Market- Recent Developments

    • 6.1 Irritable Bowel Syndrome (IBS) Therapeutics Market News and Developments

    • 6.2 Irritable Bowel Syndrome (IBS) Therapeutics Market Deals Landscape

    7 Irritable Bowel Syndrome (IBS) Therapeutics Raw Materials and Cost Structure Analysis

    • 7.1 Irritable Bowel Syndrome (IBS) Therapeutics Key Raw Materials

    • 7.2 Irritable Bowel Syndrome (IBS) Therapeutics Price Trend of Key Raw Materials

    • 7.3 Irritable Bowel Syndrome (IBS) Therapeutics Key Suppliers of Raw Materials

    • 7.4 Irritable Bowel Syndrome (IBS) Therapeutics Market Concentration Rate of Raw Materials

    • 7.5 Irritable Bowel Syndrome (IBS) Therapeutics Cost Structure Analysis

      • 7.5.1 Irritable Bowel Syndrome (IBS) Therapeutics Raw Materials Analysis

      • 7.5.2 Irritable Bowel Syndrome (IBS) Therapeutics Labor Cost Analysis

      • 7.5.3 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturing Expenses Analysis

    8 Global Irritable Bowel Syndrome (IBS) Therapeutics Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    9 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Blautix (Strain) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Bekinda (IBS-D) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global SYN-010 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Tenapanor Consumption and Growth Rate (2017-2022)

    • 9.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Research Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Outlook till 2022

    • 10.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.2.2 Canada Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.2.3 Mexico Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.2 UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.3 Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.4 Belgium Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.5 France Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.6 Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.7 Denmark Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.8 Finland Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.9 Norway Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.10 Sweden Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.11 Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.12 Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.3.13 Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.2 Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.3 India Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.4 South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.5 Pakistan Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.6 Bangladesh Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.7 Indonesia Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.8 Thailand Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.9 Singapore Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.10 Malaysia Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.11 Philippines Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.4.12 Vietnam Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.2 Colombia Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.3 Chile Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.4 Argentina Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.5 Venezuela Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.6 Peru Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.7 Puerto Rico Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.5.8 Ecuador Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.6.2 Kuwait Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.6.3 Oman Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.6.4 Qatar Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.7.2 South Africa Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.7.3 Egypt Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.7.4 Algeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

      • 10.8.2 New Zealand Irritable Bowel Syndrome (IBS) Therapeutics Consumption (2017-2022)

    11 Global Irritable Bowel Syndrome (IBS) Therapeutics Competitive Analysis

    • 11.1 Novartis

      • 11.1.1 Novartis Company Details

      • 11.1.2 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.1.4 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 GlaxoSmithKline

      • 11.2.1 GlaxoSmithKline Company Details

      • 11.2.2 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.2.4 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Astellas Pharma

      • 11.3.1 Astellas Pharma Company Details

      • 11.3.2 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.3.4 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Ardelyx

      • 11.4.1 Ardelyx Company Details

      • 11.4.2 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.4.4 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Ironwood Pharmaceuticals

      • 11.5.1 Ironwood Pharmaceuticals Company Details

      • 11.5.2 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.5.4 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Valeant Pharmaceuticals International

      • 11.6.1 Valeant Pharmaceuticals International Company Details

      • 11.6.2 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.6.4 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Abbott Laboratories

      • 11.7.1 Abbott Laboratories Company Details

      • 11.7.2 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.7.4 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Synergy Pharmaceuticals

      • 11.8.1 Synergy Pharmaceuticals Company Details

      • 11.8.2 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.8.4 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Sucampo Pharmaceuticals

      • 11.9.1 Sucampo Pharmaceuticals Company Details

      • 11.9.2 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

      • 11.9.4 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Outlook by Types and Applications to 2028

    • 12.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Blautix (Strain) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Bekinda (IBS-D) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global SYN-010 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Tenapanor Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Research Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Outlook to 2028

    • 13.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.2.2 Canada Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.2 UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.3 Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.5 France Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.6 Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.8 Finland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.9 Norway Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.11 Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.12 Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.2 Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.3 India Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.3 Chile Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.6 Peru Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.3 Oman Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Irritable Bowel Syndrome (IBS) Therapeutics

    • Figure of Irritable Bowel Syndrome (IBS) Therapeutics Picture

    • Table Global Irritable Bowel Syndrome (IBS) Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Irritable Bowel Syndrome (IBS) Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Blautix (Strain) Consumption and Growth Rate (2017-2022)

    • Figure Global Bekinda (IBS-D) Consumption and Growth Rate (2017-2022)

    • Figure Global SYN-010 Consumption and Growth Rate (2017-2022)

    • Figure Global Tenapanor Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Research Consumption and Growth Rate (2017-2022)

    • Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Table North America Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Canada Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Mexico Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Belgium Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure France Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Denmark Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Finland Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Norway Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Sweden Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table APAC Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure China Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Thailand Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Singapore Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Philippines Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table South America Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure Brazil Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Colombia Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Chile Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Argentina Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Peru Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table GCC Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure Bahrain Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Oman Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Qatar Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Africa Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure Nigeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Africa Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Egypt Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Algeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Oceania Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Country (2017-2022)

    • Figure Australia Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Irritable Bowel Syndrome (IBS) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Novartis Company Details

    • Table Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Novartis Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table GlaxoSmithKline Company Details

    • Table GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Astellas Pharma Company Details

    • Table Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Ardelyx Company Details

    • Table Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Ironwood Pharmaceuticals Company Details

    • Table Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Valeant Pharmaceuticals International Company Details

    • Table Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Abbott Laboratories Company Details

    • Table Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Synergy Pharmaceuticals Company Details

    • Table Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Table Sucampo Pharmaceuticals Company Details

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Main Business and Markets Served

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Product Portfolio

    • Figure Global Blautix (Strain) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Bekinda (IBS-D) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global SYN-010 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tenapanor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Research Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Table North America Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Germany Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure China Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Brazil Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Australia Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Irritable Bowel Syndrome (IBS) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US